HK1198467A1 - Treatment of type 2 diabetes with fty720 fty720 2 - Google Patents

Treatment of type 2 diabetes with fty720 fty720 2

Info

Publication number
HK1198467A1
HK1198467A1 HK14111955.4A HK14111955A HK1198467A1 HK 1198467 A1 HK1198467 A1 HK 1198467A1 HK 14111955 A HK14111955 A HK 14111955A HK 1198467 A1 HK1198467 A1 HK 1198467A1
Authority
HK
Hong Kong
Prior art keywords
fty720
diabetes
treatment
type
fty720 fty720
Prior art date
Application number
HK14111955.4A
Other languages
English (en)
Chinese (zh)
Inventor
Zhongmin Ma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of HK1198467A1 publication Critical patent/HK1198467A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/30Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/094Esters of phosphoric acids with arylalkanols

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK14111955.4A 2011-08-03 2014-11-27 Treatment of type 2 diabetes with fty720 fty720 2 HK1198467A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161574441P 2011-08-03 2011-08-03
PCT/US2012/049565 WO2013020069A1 (en) 2011-08-03 2012-08-03 Treatment of type 2 diabetes with fty720

Publications (1)

Publication Number Publication Date
HK1198467A1 true HK1198467A1 (en) 2015-05-08

Family

ID=46682917

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14111955.4A HK1198467A1 (en) 2011-08-03 2014-11-27 Treatment of type 2 diabetes with fty720 fty720 2

Country Status (10)

Country Link
US (2) US8653026B2 (xx)
EP (1) EP2739277B1 (xx)
JP (1) JP2014521697A (xx)
CN (1) CN103930101A (xx)
AU (1) AU2012289921B2 (xx)
CA (1) CA2843224C (xx)
DK (1) DK2739277T3 (xx)
HK (1) HK1198467A1 (xx)
MX (1) MX364643B (xx)
WO (1) WO2013020069A1 (xx)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112402610A (zh) * 2020-11-20 2021-02-26 睿阜隆(杭州)生物医药有限公司 1-磷酸鞘氨醇受体调节剂在制备治疗糖尿病的药物中的新用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE172711T1 (de) 1992-10-21 1998-11-15 Yoshitomi Pharmaceutical 2-amino-1, 3- propandiolverbindung und immunosuppressium
AU735406B2 (en) * 1997-02-27 2001-07-05 Novartis Ag Pharmaceutical composition
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
KR100659007B1 (ko) 1999-02-10 2007-02-28 미츠비시 웰파마 가부시키가이샤 아미드 화합물 및 그 의약으로서의 용도
JP3790686B2 (ja) * 2001-08-03 2006-06-28 独立行政法人理化学研究所 血糖降下剤
DE60329724D1 (de) * 2002-06-07 2009-11-26 Waratah Pharmaceuticals Inc Methoden und Kompositionen um Diabetes zu behandeln
DE60326002D1 (de) * 2002-10-22 2009-03-12 Waratah Pharmaceuticals Inc Behandlung von diabetes.
US20090176744A1 (en) * 2007-11-02 2009-07-09 Concert Pharmaceuticals, Inc. Deuterated fingolimod

Also Published As

Publication number Publication date
CA2843224C (en) 2020-04-21
CA2843224A1 (en) 2013-02-07
US8653026B2 (en) 2014-02-18
AU2012289921B2 (en) 2017-05-04
JP2014521697A (ja) 2014-08-28
NZ620025A (en) 2016-02-26
MX2014001271A (es) 2014-05-19
EP2739277B1 (en) 2016-11-23
US20140107024A1 (en) 2014-04-17
AU2012289921A1 (en) 2014-02-06
CN103930101A (zh) 2014-07-16
DK2739277T3 (en) 2017-02-27
MX364643B (es) 2019-05-03
US20130123172A1 (en) 2013-05-16
WO2013020069A1 (en) 2013-02-07
EP2739277A1 (en) 2014-06-11

Similar Documents

Publication Publication Date Title
HK1198577A1 (en) Treatment protocol of diabetes type 2
ZA201403795B (en) Formulations for the treatment of diabetes
IL222778A0 (en) Diabetes therapy
EP2793932A4 (en) CTP-BASED INSULIN ANALOGUE FOR THE TREATMENT OF DIABETES
SI2707017T1 (sl) Liksisenatid in metformin za zdravljenje sladkorne bolezni tipa 2
IL223289A0 (en) Treatment of type 2 diabetes
HK1212253A1 (en) Combinations of modalities for the treatment of diabetes
EP2867239A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
SG2014013999A (en) Improved mcm-56 manufacture
IL232566A0 (en) Diabetes treatments using isoxazole
HK1257401A1 (zh) 用於治療糖尿病和相關病症的方法和組合物
GB201117172D0 (en) Diabetes
HK1202819A1 (en) Treatment of type i and type ii diabetes i ii
HK1198467A1 (en) Treatment of type 2 diabetes with fty720 fty720 2
EP2704731A4 (en) TREATMENT OF AVIAN ORIGIN
ZA201107270B (en) A skin treatment composition
HK1196953A1 (zh) 用於治療糖尿病的製劑
ZA201401250B (en) Improved mcm-56 manufacture
GB201104872D0 (en) New compounds and medical uses
GB201104875D0 (en) New compounds and medical uses
GB201102266D0 (en) Treatment
GB201102267D0 (en) Treatment
GB201102272D0 (en) Treatment
GB201102274D0 (en) Treatment
GB201102275D0 (en) Treatment